Developing process understanding for continuous manufacturing of Lamivudine (Epivir®) Stable Form I

Ebenezer Ojo, Zied Hosni, Iyke Onyemelukwe, Lennart Ramakers, Ian Houson, Alastair Florence

Research output: Contribution to conferencePoster

Abstract

Why the considerations for Lamivudine?
* Increasing numbers of HIV/AIDS infections on yearly basis (2.1 million new cases in 2015, UNAIDS)
* Hepatitis B infections (257 million cases globally, WHO)
* Currently FDA-approved antiretroviral therapy for the prevention and treatment of both viral infections (FDA).

Key research considerations and interests
To the best of our knowledge, no publication yet exists on continuous manufacturing of stable Lamivudine form 1. The key research question here is:
* Translate current batch crystallisation into a continuous process?
* Improve the downstream process-ability by modifying the particle properties?
* Develop miniaturise platforms for accelerated process development?

Conference

Conference50th Annual Conference of the British Association of Crystal Growth
CountryUnited Kingdom
CityLondon
Period9/07/1911/07/19

Fingerprint

Lamivudine
Virus Diseases
Crystallization
Hepatitis B
Research
HIV Infections
Publications
Acquired Immunodeficiency Syndrome
Infection
Therapeutics

Keywords

  • autonomous platform
  • crystallisation
  • anti-retroviral
  • Lamivudine
  • process development

Cite this

Ojo, E., Hosni, Z., Onyemelukwe, I., Ramakers, L., Houson, I., & Florence, A. (2019). Developing process understanding for continuous manufacturing of Lamivudine (Epivir®) Stable Form I. Poster session presented at 50th Annual Conference of the British Association of Crystal Growth, London, United Kingdom. https://doi.org/10.6084/m9.figshare.9775382.v1
Ojo, Ebenezer ; Hosni, Zied ; Onyemelukwe, Iyke ; Ramakers, Lennart ; Houson, Ian ; Florence, Alastair. / Developing process understanding for continuous manufacturing of Lamivudine (Epivir®) Stable Form I. Poster session presented at 50th Annual Conference of the British Association of Crystal Growth, London, United Kingdom.1 p.
@conference{5e6806cbe6ac4f32849668b611c44ad6,
title = "Developing process understanding for continuous manufacturing of Lamivudine (Epivir{\circledR}) Stable Form I",
abstract = "Why the considerations for Lamivudine?* Increasing numbers of HIV/AIDS infections on yearly basis (2.1 million new cases in 2015, UNAIDS)* Hepatitis B infections (257 million cases globally, WHO)* Currently FDA-approved antiretroviral therapy for the prevention and treatment of both viral infections (FDA).Key research considerations and interestsTo the best of our knowledge, no publication yet exists on continuous manufacturing of stable Lamivudine form 1. The key research question here is:* Translate current batch crystallisation into a continuous process?* Improve the downstream process-ability by modifying the particle properties?* Develop miniaturise platforms for accelerated process development?",
keywords = "autonomous platform, crystallisation, anti-retroviral, Lamivudine, process development",
author = "Ebenezer Ojo and Zied Hosni and Iyke Onyemelukwe and Lennart Ramakers and Ian Houson and Alastair Florence",
year = "2019",
month = "7",
day = "9",
doi = "10.6084/m9.figshare.9775382.v1",
language = "English",
note = "50th Annual Conference of the British Association of Crystal Growth ; Conference date: 09-07-2019 Through 11-07-2019",

}

Ojo, E, Hosni, Z, Onyemelukwe, I, Ramakers, L, Houson, I & Florence, A 2019, 'Developing process understanding for continuous manufacturing of Lamivudine (Epivir®) Stable Form I' 50th Annual Conference of the British Association of Crystal Growth, London, United Kingdom, 9/07/19 - 11/07/19, . https://doi.org/10.6084/m9.figshare.9775382.v1

Developing process understanding for continuous manufacturing of Lamivudine (Epivir®) Stable Form I. / Ojo, Ebenezer; Hosni, Zied; Onyemelukwe, Iyke; Ramakers, Lennart; Houson, Ian; Florence, Alastair.

2019. Poster session presented at 50th Annual Conference of the British Association of Crystal Growth, London, United Kingdom.

Research output: Contribution to conferencePoster

TY - CONF

T1 - Developing process understanding for continuous manufacturing of Lamivudine (Epivir®) Stable Form I

AU - Ojo, Ebenezer

AU - Hosni, Zied

AU - Onyemelukwe, Iyke

AU - Ramakers, Lennart

AU - Houson, Ian

AU - Florence, Alastair

PY - 2019/7/9

Y1 - 2019/7/9

N2 - Why the considerations for Lamivudine?* Increasing numbers of HIV/AIDS infections on yearly basis (2.1 million new cases in 2015, UNAIDS)* Hepatitis B infections (257 million cases globally, WHO)* Currently FDA-approved antiretroviral therapy for the prevention and treatment of both viral infections (FDA).Key research considerations and interestsTo the best of our knowledge, no publication yet exists on continuous manufacturing of stable Lamivudine form 1. The key research question here is:* Translate current batch crystallisation into a continuous process?* Improve the downstream process-ability by modifying the particle properties?* Develop miniaturise platforms for accelerated process development?

AB - Why the considerations for Lamivudine?* Increasing numbers of HIV/AIDS infections on yearly basis (2.1 million new cases in 2015, UNAIDS)* Hepatitis B infections (257 million cases globally, WHO)* Currently FDA-approved antiretroviral therapy for the prevention and treatment of both viral infections (FDA).Key research considerations and interestsTo the best of our knowledge, no publication yet exists on continuous manufacturing of stable Lamivudine form 1. The key research question here is:* Translate current batch crystallisation into a continuous process?* Improve the downstream process-ability by modifying the particle properties?* Develop miniaturise platforms for accelerated process development?

KW - autonomous platform

KW - crystallisation

KW - anti-retroviral

KW - Lamivudine

KW - process development

U2 - 10.6084/m9.figshare.9775382.v1

DO - 10.6084/m9.figshare.9775382.v1

M3 - Poster

ER -

Ojo E, Hosni Z, Onyemelukwe I, Ramakers L, Houson I, Florence A. Developing process understanding for continuous manufacturing of Lamivudine (Epivir®) Stable Form I. 2019. Poster session presented at 50th Annual Conference of the British Association of Crystal Growth, London, United Kingdom. https://doi.org/10.6084/m9.figshare.9775382.v1